PI Industries to acquire API business of lnd Swift Laboratories

PI Industries Ltd, an Indian agri-sciences company, has agreed to acquire the API business division of lnd Swift Laboratories Limited (ISLL) for INR 1,530 crores ($210 million).

Based in Chandigarh, lnd Swift Laboratories manufactures and exports active pharmaceutical ingredients (API) and advanced intermediates. The Indian pharma company serves the API requirements of regulated and soft regulated markets.

The API unit of lnd Swift Laboratories has more than 20 products. Of which, several of its API products are in the global top 5 positions.

The business is also said to have a good research and development (R&D) product pipeline.

PI Industries to acquire API business of lnd Swift Laboratories
PI Industries to acquire API business of lnd Swift Laboratories. Photo courtesy of Free-Photos from Pixabay.

PI Industries said that over the last few years, it has also developed a robust R&D pipeline of products and complementary technologies. The agri-sciences company added that introducing new and cutting-edge technologies will also allow building a differentiated and sustainable relationship with overseas customers.

Based on satisfactory completion of the preceding conditions, the deal is expected to close within three months.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Can High Tide’s Remexian acquisition turn it into a global cannabis leader? €26.4m deal explained
Total
0
Shares
Related Posts
Read More

Vertex to acquire Semma Therapeutics to advance stem cell-based treatments for type 1 diabetes

Vertex acquisition of Semma Therapeutics : US biotechnology company Vertex Pharmaceuticals has agreed to acquire privately-held biotechnology company Semma Therapeutics for $950 million in cash, as per the latest pharma acquisition news. Both the pharma companies are based in Massachusetts. Post-acquisition, Vertex Pharmaceuticals will advance curative cell-based treatments of Semma Therapeutics for type 1 diabetes and […]

The post Vertex to acquire Semma Therapeutics to advance stem cell-based treatments for type 1 diabetes appeared first on PharmaNewsDaily.com.